Shenzhen Salubris Pharmaceuticals Co., Ltd. (SHE: 002294) announced clinical trial approval from China’s National Medical Products Administration (NMPA) for SAL0150, an in-house developed oral long-acting drug for type 2 diabetes mellitus, obesity/overweight, and type 2 diabetes with peripheral arterial disease (accompanied by intermittent claudication). The candidate aims to achieve once-weekly or less frequent oral dosing, positioning Salubris in the competitive GLP-1/oral incretin space with potential convenience advantages over current standards.
Good therapeutic efficacy on metabolic and cardiovascular endpoints; favorable safety profile
Development Status
NMPA IND approval; Phase I/II initiation imminent
Strategic Context & Competitive Landscape
Factor
Implication
China Diabetes/Obesity Market
~140 million T2DM patients; 50%+ overweight/obesity; RMB 100+ billion annual drug market growing at 15% CAGR
GLP-1 Oral Gap
Oral semaglutide (Rybelsus) daily dosing; no approved weekly oral incretin in China – significant unmet need for convenience
SAL0150 Differentiation
Once-weekly oral would disrupt injectable GLP-1 dominance (semaglutide, tirzepatide) and challenge daily oral alternatives
Peripheral Arterial Disease (PAD)
30–50% of T2DM patients develop PAD; intermittent claudication indication addresses cardiovascular-metabolic convergence – differentiated vs. pure weight-loss focus
Competitive Landscape
Oral GLP-1s in development: Orforglipron (Eli Lilly, Phase III), AZD5004 (AstraZeneca); SAL0150’s weekly frequency + PAD indication provides positioning niche
Development Timeline: Phase I PK/PD Q2 2026; Phase II efficacy 2027; potential fast-track NDA 2029 if Phase IIb demonstrates non-inferiority to injectable GLP-1s
Commercial Potential: Peak China sales RMB 2–4 billion annually assuming weekly oral convenience captures 10–15% of T2DM/obesity market; PAD indication adds RMB 500+ million vascular protection segment
Forward‑Looking Statements This brief contains forward‑looking statements regarding clinical trial execution, dosing frequency validation, and commercial potential for SAL0150. Actual results may differ due to pharmacokinetic challenges with oral peptide delivery, competitive dynamics with injectable GLP-1s, and reimbursement negotiations for oral diabetes/obesity therapies.-Fineline Info & Tech
By Fineline Cube